Related Experiment Video

Updated: Jul 27, 2026

Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach
09:57

Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach

Published on: December 17, 2016

Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor

M Groll1, Y Koguchi, R Huber

  • 1Max-Planck-Institut für Biochemie, Martinsried, D-82152, Germany. groll@biochem.mpg.de

Journal of Molecular Biology
|August 9, 2001
PubMed

Insights

Researchers characterized the yeast proteasome core particle (CP) with TMC-95A, a novel inhibitor. This study reveals how TMC-95A non-covalently blocks CP active sites, aiding the development of new anti-cancer and anti-inflammatory drugs.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Molecular Biology

Background:

  • The 20 S proteasome core particle (CP) is a multicatalytic protease crucial for cellular processes like immune response and cell-cycle control.
  • Selective inhibition of the CP offers a therapeutic strategy for various diseases.

Purpose of the Study:

  • To biochemically and crystallographically characterize the yeast proteasome core particle (CP) in complex with the natural product TMC-95A.
  • To understand the binding mechanism of TMC-95A to the CP.

Main Methods:

  • Biochemical assays
  • X-ray crystallography
  • Structural analysis of the yeast proteasome-TMC-95A complex

Main Results:

  • TMC-95A, a novel heterocyclic compound, was found to specifically and non-covalently inhibit the CP active sites.
  • The inhibitor binds to the CP via specific hydrogen bonds with protein main-chain atoms.
  • Structural analysis identified essential portions of TMC-95s for proteasome binding.

Conclusions:

  • TMC-95A provides a unique model for understanding proteasome inhibition.
  • The findings lay the groundwork for developing synthetic selective proteasome inhibitors.
  • These inhibitors show promise as potential anti-tumoral and anti-inflammatory drugs.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

X-Ray Crystallography to Study the Oligomeric State Transition of the Thermotoga maritima M42 Aminopeptidase TmPep105011:27

X-Ray Crystallography to Study the Oligomeric State Transition of the Thermotoga maritima M42 Aminopeptidase TmPep1050

Published on: May 13, 2020

Related Concept Videos

Protein Complexes with Interchangeable Parts01:57

Protein Complexes with Interchangeable Parts

Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Protein Complexes with Interchangeable Parts01:57

Protein Complexes with Interchangeable Parts

Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...